{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:14:10Z","timestamp":1775646850956,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T00:00:00Z","timestamp":1238716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s12185-009-0290-9","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T02:28:40Z","timestamp":1238639320000},"page":"482-488","source":"Crossref","is-referenced-by-count":16,"title":["Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR"],"prefix":"10.1007","volume":"89","author":[{"given":"Masahide","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Kakihana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tadokoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,3]]},"reference":[{"key":"290_CR1","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321\u201331. doi:\n                    10.1038\/sj.leu.2403426\n                    \n                  .","journal-title":"Leukemia"},{"key":"290_CR2","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190\u20136. doi:\n                    10.1038\/sj.leu.2402741\n                    \n                  .","journal-title":"Leukemia"},{"key":"290_CR3","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin AS, La Ros\u00e9e P, Stoffregen EP, et al. Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101:4611\u20134. doi:\n                    10.1182\/blood-2002-12-3659\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR4","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1073\/pnas.0409770102","volume":"102","author":"MR Burgess","year":"2005","unstructured":"Burgess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA. 2005;102:3395\u2013400. doi:\n                    10.1073\/pnas.0409770102\n                    \n                  .","journal-title":"Proc Natl Acad Sci USA"},{"key":"290_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399\u2013401. doi:\n                    10.1126\/science.1099480\n                    \n                  .","journal-title":"Science"},{"key":"290_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O\u2019Hare","year":"2006","unstructured":"O\u2019Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. 2006;16:92\u20139. doi:\n                    10.1016\/j.gde.2005.11.002\n                    \n                  .","journal-title":"Curr Opin Genet Dev"},{"key":"290_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","volume":"66","author":"MA Young","year":"2006","unstructured":"Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006;66:1007\u201314. doi:\n                    10.1158\/0008-5472.CAN-05-2788\n                    \n                  .","journal-title":"Cancer Res"},{"key":"290_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007;109:500\u20132. doi:\n                    10.1182\/blood-2006-05-025049\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR9","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","volume":"106","author":"SG Willis","year":"2005","unstructured":"Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106:2128\u201337. doi:\n                    10.1182\/blood-2005-03-1036\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR10","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005\u201311. doi:\n                    10.1182\/blood-2007-03-080838\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112:53\u20135. doi:\n                    10.1182\/blood-2007-11-123950\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3324\/haematol.11993","volume":"93","author":"T Ernst","year":"2008","unstructured":"Ernst T, Erben P, M\u00fcller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008;93:186\u201392. doi:\n                    10.3324\/haematol.11993\n                    \n                  .","journal-title":"Haematologica"},{"key":"290_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/10245332.2001.11746579","volume":"6","author":"N Kono","year":"2001","unstructured":"Kono N, Ohashi K, Okuyama Y, et al. Treatment of relapsing Ph+ acute lymphoblastic leukemia with donor leukocyte infusion followed by quantitative monitoring of residual disease. Hematology. 2001;6:261\u20135.","journal-title":"Hematology"},{"key":"290_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.clinbiochem.2003.11.011","volume":"37","author":"Y Mashima","year":"2004","unstructured":"Mashima Y, Nagano M, Funayama T, et al. Rapid quantification of the heteroplasmy of mutant mitochondrial DNAs in Leber\u2019s hereditary optic neuropathy using the Invader technology. Clin Biochem. 2004;37:268\u201376. doi:\n                    10.1016\/j.clinbiochem.2003.11.011\n                    \n                  .","journal-title":"Clin Biochem"},{"key":"290_CR15","doi-asserted-by":"publisher","first-page":"8272","DOI":"10.1073\/pnas.140225597","volume":"97","author":"JG Hall","year":"2000","unstructured":"Hall JG, Eis PS, Law SM, et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci USA. 2000;97:8272\u20137. doi:\n                    10.1073\/pnas.140225597\n                    \n                  .","journal-title":"Proc Natl Acad Sci USA"},{"key":"290_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1084-8592(99)80012-5","volume":"4","author":"RW Kwiatkowski","year":"1999","unstructured":"Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B. Clinical, genetic, and pharmacogenetic applications of invader assay. Mol Diagn. 1999;4:353\u201364. doi:\n                    10.1016\/S1084-8592(99)80012-5\n                    \n                  .","journal-title":"Mol Diagn"},{"key":"290_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337. doi:\n                    10.1182\/blood-2006-01-0092\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.leukres.2005.02.006","volume":"29","author":"S Hayette","year":"2005","unstructured":"Hayette S, Michallet M, Baille ML, et al. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leuk Res. 2005;29:1073\u20137. doi:\n                    10.1016\/j.leukres.2005.02.006\n                    \n                  .","journal-title":"Leuk Res"},{"key":"290_CR19","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMc035089","volume":"348","author":"C Roche-Lestienne","year":"2003","unstructured":"Roche-Lestienne C, Lai JL, Darre S, et al. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med. 2003;348:2265\u20136. doi:\n                    10.1056\/NEJMc035089\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"290_CR20","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374\u20139. doi:\n                    10.1158\/1078-0432.CCR-06-1516\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"290_CR21","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","volume":"104","author":"S Branford","year":"2004","unstructured":"Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926\u201332. doi:\n                    10.1182\/blood-2004-03-1134\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N Bubnoff von","year":"2006","unstructured":"von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328\u201333. doi:\n                    10.1182\/blood-2005-12-010132\n                    \n                  .","journal-title":"Blood"},{"key":"290_CR23","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T, Johnson KJ, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332\u20138. doi:\n                    10.1182\/blood-2006-02-004580\n                    \n                  .","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0290-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-009-0290-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0290-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0290-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:01:24Z","timestamp":1559437284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-009-0290-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1007\/s12185-009-0290-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,3]]}}}